|Bid||33.04 x 300|
|Ask||33.07 x 300|
|Day's Range||31.50 - 33.39|
|52 Week Range||14.83 - 63.73|
|PE Ratio (TTM)||-13.55|
|Earnings Date||Jul 17, 2017 - Jul 21, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||60.94|
Despite a rising market, these stocks fell. Find out why.
Some big name money managers shared their best long and short ideas at the SALT Conference.
Barron's Andrew Bary has been a Sarepta Therapeutics (SRPT) bull for a while now, most recently arguing that the stock could double. Karp notes that Sarepta's treatment for Duchenne muscular dystrophy, though lacking the same kind of data that drugs with higher prevalence rates might have, appears to work quite well. Patients on the drug have better respiratory function and a greater walking ability than they have without it.